Cefotetan: Difference between revisions
No edit summary |
No edit summary |
||
| Line 28: | Line 28: | ||
'''| [[Cefotetan adverse reactions|Adverse Reactions]]''' | '''| [[Cefotetan adverse reactions|Adverse Reactions]]''' | ||
'''| [[Cefotetan overdosage|Overdosage]]''' | '''| [[Cefotetan overdosage|Overdosage]]''' | ||
'''| [[Cefotetan dosage and administration|Dosage and Administration]]''' | '''| [[Cefotetan dosage and administration|Dosage and Administration]]''' | ||
'''| [[Cefotetan Compatibility and Stability|Compatibility and Stability]]''' | '''| [[Cefotetan Compatibility and Stability|Compatibility and Stability]]''' | ||
Revision as of 08:41, 10 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
For patient information, click here
Overview
Cefotetan is an injectable antibiotic of the cephamycin type for prophylaxis and treatment of bacterial infections. It is often grouped together with second-generation cephalosporins and has a similar antibacterial spectrum, but with additional anti-anaerobe converage.
Cefotetan was developed by Yamanouchi. It is marketed outside Japan by AstraZeneca with the brand names Apatef and Cefotan.
Category
Cephalosporins, second generation.
US Brand Names
CEFOTETAN®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Dosage and Administration | Compatibility and Stability | How Supplied | Labels and Packages
References
http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50588slr027_cefotan_lbl.pdf